It was a pleasure to meet with Prof. Eric Daar (Harbor-UCLA Medical Center, West Carson, CA, USA) to discuss his study investigating metabolic complications among treatment-naïve adults living with HIV-1. Part 1 of this interview can be found here.
The abstract entitled: ‘Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- What were the aims and methodology of your study investigating metabolic complications among treatment-naïve adults living with HIV-1? (0:18)
- What were the findings for each treatment regimen studied? (2:11)
- What were the strengths and limitations of this study? (5:16)
- What questions remain unanswered and what future studies are planned? (6:54)
Disclosures: Eric Daar is a consultant for Gilead and Merck, and receives research support from Gilead, Merck and ViiV Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
